Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results [Yahoo! Finance]
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: Yahoo! Finance
Dive Brief: Pfizer and partner Valneva said Monday they plan to seek regulatory approval of their experimental Lyme disease vaccine even though the shot missed its main goal in a late-stage trial. Pfizer and Valneva said that by one analysis, the vaccine, LB6V, was 73% effective compared to a placebo at preventing Lyme disease 28 days after the fourth dose. A second analysis found it roughly 75% effective one day after the fourth dose. However, the vaccine still failed to meet its primary objective because fewer-than-expected Lyme disease cases accrued over the course of the study period. Despite the setback, the partners characterized the efficacy results as “clinically meaningful” and said they're “confident in the vaccine's potential.” Approval applications are planned. Still, Valneva shares fell by more than 35% in early trading Monday. Dive Insight: Lyme disease is spread by infected ticks and can be treated with antibiotics if caught early. But if it isn't, the diseas
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALNGlobeNewswire
- Pfizer Lyme Vaccine Data Adds New Angle To Vaccine Portfolio Story [Yahoo! Finance]Yahoo! Finance
- Mixed results for Lyme disease vaccine hit Valneva shares [Yahoo! Finance]Yahoo! Finance
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss [CNBC]CNBC
- Valneva Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
VALN
Sec Filings
- 3/18/26 - Form 6-K
- 3/17/26 - Form 20-F
- 3/10/26 - Form SCHEDULE
- VALN's page on the SEC website